Extended Release Sialic Acid Formulations for Stable Serum Levels
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for sialic acid deficiencies, such as Hereditary Inclusion Body Myopathy (HIBM), face challenges due to rapid clearance and excretion of sialic acid metabolites, leading to fluctuating serum levels and inadequate tissue availability, which complicates effective substrate replacement and varies across individuals with different genetic mutations.
Innovation Solution
Development of extended release pharmaceutical formulations comprising sialic acid and its derivatives, combined with specific polymers like hypromellose, alginate, and carrageenan, to provide sustained delivery of therapeutically effective amounts over 12 hours or more, ensuring steady exposure and minimizing feedback inhibition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If sialic acid metabolites are administered to treat sialic acid deficiencies, then therapeutic effect is achieved, but rapid clearance and excretion lead to fluctuating serum levels and inadequate tissue availability
Solution Approach 1:
The patent divides the single dose administration into multiple smaller doses administered at intervals, or uses extended-release formulations that segment the release of sialic acid metabolites over time. This segmentation maintains more stable serum levels and improves tissue availability by preventing rapid clearance between doses.
Solution Approach 2:
The patent employs precursors such as N-acetylmannosamine (ManNAc) that are converted endogenously to sialic acid. This preliminary action allows the body's own metabolic pathways to produce sialic acid at a controlled rate, avoiding the rapid clearance issues of direct sialic acid administration while maintaining therapeutic efficacy.
2Quantity of substance
If high doses of sialic acid metabolites are administered to ensure adequate tissue availability, then therapeutic effect improves, but feedback inhibition increases and variability in individual responses varies across individuals with different genetic mutations
Solution Approach 1:
By administering precursors like ManNAc rather than sialic acid directly, the patent allows endogenous conversion at controlled rates through the GNE enzyme pathway. This preliminary conversion step bypasses feedback inhibition mechanisms that would otherwise limit direct sialic acid supplementation, enabling more effective substrate replacement without triggering harmful feedback responses.
Solution Approach 2:
The patent uses N-acetylmannosamine as an intermediary substance that converts to sialic acid through endogenous enzymatic pathways. This intermediary approach allows controlled production of sialic acid without directly overwhelming feedback inhibition mechanisms, and the conversion rate can be modulated by the body's own metabolic regulation.
Data Source
AI summary
The present invention relates to compositions and methods for treating sialic acid deficiencies comprising extended release formulations.